ICU Medical raises 2026 guidance as Q2 adjusted EPS rises to $2.37
ICU Medical reported second quarter 2026 GAAP revenue of $551.7 million, up 1% from a year earlier, and adjusted diluted earnings per share of $2.37, up from $2.10. GAAP net income fell to $19.1 million from $35.3 million, a year-over-year comparison that includes a $41.8 million gain on the 2025 sale of the IV Solutions business. The company raised its fiscal 2026 guidance, including adjusted EBITDA of $415 million to $435 million and adjusted diluted EPS of $8.60 to $9.00.
Key points
- Q2 2026 GAAP revenue was $551.7 million, up 1%; organic revenue, excluding the IV Solutions divestiture and currency, rose 6%.
- Q2 2026 GAAP diluted EPS was $0.76, versus $1.43 a year earlier, when results included a $41.8 million gain on sale of business.
- Adjusted EBITDA was $110.0 million, compared with $100.3 million in Q2 2025.
- Fiscal 2026 guidance: GAAP net income raised to $73 million to $83 million from $26 million to $44 million; adjusted diluted EPS raised to $8.60 to $9.00 from $7.75 to $8.45.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.